These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17179687)

  • 1. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study.
    Song C; Park JT; Heo KO; Lee KS; Choo MS
    J Korean Med Sci; 2006 Dec; 21(6):1060-3. PubMed ID: 17179687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
    Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
    J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of combined behavioral intervention and tolterodine on patient-reported outcomes.
    Wyman JF; Klutke C; Burgio K; Guan Z; Sun F; Berriman S; Bavendam T
    Can J Urol; 2010 Aug; 17(4):5283-90. PubMed ID: 20735908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder.
    Mattiasson A; Blaakaer J; Høye K; Wein AJ;
    BJU Int; 2003 Jan; 91(1):54-60. PubMed ID: 12614251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial.
    Tang H; Chen J; Wang Y; Yu T; Guo C; Liao X
    Urol J; 2014 Sep; 11(4):1800-5. PubMed ID: 25194079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS; Doo CK; Lee KS
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
    Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
    Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.